BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 15, 2026
See today's BioWorld Asia
Home
» Daiichi buying Ambit for $410M; quizartinib phase III ongoing
To read the full story,
subscribe
or
sign in
.
Daiichi buying Ambit for $410M; quizartinib phase III ongoing
Oct. 1, 2014
By
Karen Carey
In a deal valued at up to $410 million, Tokyo's Daiichi Sankyo Co. Ltd. offered to buy San Diego-based Ambit Biosciences Inc., along with its pivotal-stage cancer drug quizartinib.
BioWorld Asia
